[go: up one dir, main page]

MX2008013724A - Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel. - Google Patents

Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.

Info

Publication number
MX2008013724A
MX2008013724A MX2008013724A MX2008013724A MX2008013724A MX 2008013724 A MX2008013724 A MX 2008013724A MX 2008013724 A MX2008013724 A MX 2008013724A MX 2008013724 A MX2008013724 A MX 2008013724A MX 2008013724 A MX2008013724 A MX 2008013724A
Authority
MX
Mexico
Prior art keywords
hydrogen sulfate
preparation
polymorphic forms
clopidogrel hydrogen
relates
Prior art date
Application number
MX2008013724A
Other languages
English (en)
Inventor
Chidambaram Venkateswaran Srinivasan
Rahul Saxena
Naresh Kumar Verma
Lalit Wadhwa
Original Assignee
Ind Swift Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Swift Lab Ltd filed Critical Ind Swift Lab Ltd
Publication of MX2008013724A publication Critical patent/MX2008013724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con un nuevo proceso para la preparación de formas polimórficas de hidrógeno sulfato de clopidogrel, principalmente hidrógeno sulfato de clopidogrel de metil (+)-(S)-a-(o-clorofenil)-6,7-dihidrotieno [3,2-c] piridina-5(4H )-acetato de fórmula I. Particularmente la presente invención se relaciona con un proceso para la preparación de hidrógeno sulfato de clopidogrel de forma (I) y amorfo.
MX2008013724A 2006-04-27 2007-04-25 Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel. MX2008013724A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1075DE2006 2006-04-27
IN1794DE2006 2006-08-08
PCT/IN2007/000163 WO2007125544A2 (en) 2006-04-27 2007-04-25 Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate

Publications (1)

Publication Number Publication Date
MX2008013724A true MX2008013724A (es) 2009-06-19

Family

ID=38655911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013724A MX2008013724A (es) 2006-04-27 2007-04-25 Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.

Country Status (10)

Country Link
US (1) US20090099363A1 (es)
EP (1) EP2012781A2 (es)
JP (1) JP2009543759A (es)
KR (1) KR20090013794A (es)
CN (1) CN102014899A (es)
CA (1) CA2650471A1 (es)
MA (1) MA30473B1 (es)
MX (1) MX2008013724A (es)
RU (1) RU2008146758A (es)
WO (1) WO2007125544A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825093A (en) * 2006-08-03 2008-06-16 Teva Pharma Process for preparing clopidogrel bisulphate
PL382055A1 (pl) * 2007-03-23 2008-09-29 Koźluk Tomasz Nobilus Ent Sposób wytwarzania formy krystalicznej 1 wodorosiarczanu klopidogrelu
WO2010046852A1 (en) * 2008-10-20 2010-04-29 Ranbaxy Laboratories Limited Process for the preparation of clopidogrel hydrogen sulphate form 1
CN102199160B (zh) * 2011-03-22 2016-06-22 浙江华海药业股份有限公司 一种制备ⅰ型硫酸氢氯吡格雷的方法
CN102443010A (zh) * 2011-11-05 2012-05-09 江南大学 一种无定形氯吡格雷硫酸氢盐的制备方法
CN102432625A (zh) * 2011-11-05 2012-05-02 江南大学 一种制备高纯度i型氯吡格雷硫酸氢盐的结晶方法
CN102875568B (zh) * 2012-09-06 2015-12-09 苏州晶云药物科技有限公司 制备(+)-(s)-氯吡格雷硫酸氢盐纯晶型i的方法
WO2014118802A1 (en) * 2013-01-31 2014-08-07 Pharmazell Gmbh An improved process for the preparation of clopidogrel bisulfate form-i
CN105218559A (zh) * 2015-10-21 2016-01-06 云南省药物研究所 一种稳定的非晶态硫酸氢氯吡格雷复合物
CN113121559B (zh) * 2019-12-31 2023-08-29 惠州信立泰药业有限公司 一种高堆密度的ii型硫酸氢氯吡格雷球形结晶及制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2664276B1 (fr) * 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
HU225504B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them
HU225503B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them
HU222283B1 (hu) * 1997-05-13 2003-05-28 Sanofi-Synthelabo Eljárás tieno[3,2-c]piridin-származékok előállítására
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) * 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
WO2004048385A2 (en) * 2002-11-28 2004-06-10 Instytut Farmaceutyczny A process for the preparation of crystalline form 1 or clopidogrel hydrogen sulfate
WO2004081015A1 (en) * 2003-03-10 2004-09-23 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
WO2004081016A1 (en) * 2003-03-12 2004-09-23 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
US20060047121A1 (en) * 2004-09-01 2006-03-02 Sawant Kamlesh D Novel process for preparation of clopidogrel bisulfate polymorph - Form I
US7446200B2 (en) * 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
US7772398B2 (en) * 2005-03-11 2010-08-10 Dr. Reddy's Laboratories, Inc. Process for making crystalline form I of clopidogrel hydrogen sulphate
US20070191609A1 (en) * 2006-02-13 2007-08-16 Lee Pharma Limited Process for preparation of clopidogrel bisulphate form-1
US20070225320A1 (en) * 2006-03-27 2007-09-27 Eswaraiah Sajja Process for preparing clopidogrel
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I

Also Published As

Publication number Publication date
CA2650471A1 (en) 2007-11-08
JP2009543759A (ja) 2009-12-10
EP2012781A2 (en) 2009-01-14
KR20090013794A (ko) 2009-02-05
MA30473B1 (fr) 2009-06-01
WO2007125544A2 (en) 2007-11-08
US20090099363A1 (en) 2009-04-16
CN102014899A (zh) 2011-04-13
RU2008146758A (ru) 2010-06-10
WO2007125544A3 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
MX2008013724A (es) Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.
ZA200809967B (en) Thieno[3,2-D] pyrimidine derivative useful as PI3K inhibitor
PL1740593T3 (pl) Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
IL189667A0 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
IL206758A0 (en) Furo-and thieno [3,2-c] pyridines
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
SI1513846T1 (sl) Postopek za pripravo olanzapina form I
EP1651646A4 (en) NEW PROCESS FOR THE PREPARATION OF (+) - (S) -CLOPIDOGREL BISULFATE OF FORM I
NZ618902A (en) Modulators of 5-ht receptors and methods of use thereof
PL1656381T3 (pl) Krystalizacja stałych postaci soli addycyjnych klopidogrelu
HU0301082D0 (en) Novel polymorphous forms of olanzapine hydrochloride
IL192825A0 (en) A PROCESS FOR THE PREPARATION OF POLYMORPH FORM I OF (S)-(+)-METHYL-ßé?- (2-CHLOROPHENYL)-6,7-DYHIDRO-THIENO-[3,2-C]PYRIDINE-5(4H)-ACETATE HYDROGEN SULFATE
MX2009001141A (es) Derivados de acido tieno[3,2-c]piridin-2-carboxilico.
PL354642A1 (en) Method of manufacture of alanzapine, new derivative of n-demethyl olanzapine and method of manufacture of new derivative of n-demethyl olanzapine
IL164978A0 (en) A process for the preparation of clopidogrel
WO2007087555A3 (en) Novel polymorph 'form e ' of olanzapine (2-methyl-4- (4-methyl-1-piperazinyl) -10h-thieno [2, 3-b] [1, 5] benzodiazepine) and preparation of the anhydrous non-solvated crystalline polymorphic 'form i' of olanzapine from the polymorphic olanzapine 'form e'
HU0700809D0 (en) Racemisation process for producing methyl (r,s)-(+)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)-acetate hydrogene sulfate intermediate
EA201290535A1 (ru) Способ получения фармацевтических соединений и промежуточных соединений
UA86772C2 (en) Process for the preparation of the polymorph form of methyl (s)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate
HUP0401269A3 (en) Process for the production of amorphous form of clopidogrel hydrogen sulfate
WO2005003138A3 (en) Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
PL380849A1 (pl) Krystaliczna postać racemicznego -(2-chlorofenylo)-6,7-dihydrotieno[3,2-c]pirydylo-5(4H)-octanu metylu, sposób jej wytwarzania i zastosowanie
WO2008108742A3 (en) Polymorphic forms of clopidogrel hydrobromide
EA201001278A1 (ru) Способ получения оланзапина
PL2024372T3 (pl) Pochodna tieno[3,2-D]pirymidyny użyteczna jako inibitor PI3K